68镓-PSMA PET/CT引导机器人辅助挽救性淋巴结清扫的初始多中心经验:安全性可接受但肿瘤学获益似乎有限
这项多中心研究纳入35例68镓-PSMA PET/CT检出寡转移淋巴结复发的前列腺癌患者,接受机器人辅助挽救性淋巴结清扫。中位随访12个月时,无生化复发生存率为23%,临床无复发生存率为66%,仅23%患者出现Clavien-Dindo≤2级并发症。作者认为该手术安全可行但肿瘤学获益有限,推荐严格筛选患者并限于临床试验。
要点
- 35例患者中32例(91%)病理证实淋巴结转移,中位每例2枚转移淋巴结。
- 中位随访12个月,无生化复发生存率23%,临床无复发生存率66%。
- 仅23%患者出现Clavien-Dindo≤2级并发症,无更高等级并发症报告。
核心结论
- 机器人辅助挽救性淋巴结清扫看似安全可行,但不足半数患者获得治疗反应,中位随访12个月时不足四分之一患者无生化复发。
- 68镓-PSMA显像低估微转移病灶,因此该手术很少能达治愈。
- 作者建议严格筛选患者并将该手术限于临床试验,需长期随访评估生活质量和死亡获益。
研究设计与样本
- 多中心研究,纳入2014年2月至2016年4月两家中心共35例68镓-PSMA PET/CT检出寡转移淋巴结复发的前列腺癌患者。
- 手术方式包括靶向盆腔清扫、单侧扩大盆腔模板清扫或双侧扩大盆腔模板清扫,取决于既往盆腔治疗及淋巴结病变范围/位置。
- 并发症采用Clavien-Dindo分级系统报告,治疗反应预测因素采用单因素二元逻辑回归分析。
主要发现
- 68镓-PSMA显像共检出35例患者中58个可疑淋巴结转移病灶。
- 32例(91%)患者经病理证实淋巴结转移,共87枚转移淋巴结,中位(四分位距)每例2(1-3)枚。
- 8例(23%)患者出现并发症,均为Clavien-Dindo≤2级。
- 宽泛定义下15例(43%)获治疗反应,严格定义下11例(31%)获治疗反应。
- 全队列中位随访12个月时,无生化复发生存率为23%,临床无复发生存率为66%。
关键数值与推荐
- 治疗反应宽泛定义:既往根治性前列腺切除者术后6周PSA<0.2 ng/mL;既往放疗者术后6周PSA低于放疗后最低值。
- 治疗反应严格定义:既往根治性前列腺切除者术后6周PSA<0.05 ng/mL。
- 生化复发定义:既往根治性前列腺切除者PSA>0.2 ng/mL;既往放疗者PSA高于最低值。
临床怎么用
- 作者建议严格筛选患者并将机器人辅助挽救性淋巴结清扫限于临床试验。
- 作者指出68镓-PSMA显像低估微转移病灶,该手术很少能达治愈。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the safety and short-term oncological outcomes of 68 gallium-labelled prostate-specific membrane antigen (68 Ga-PSMA) positron-emission tomography (PET)/computed tomography (CT)-directed robot-assisted salvage node dissection (RASND) for prostate cancer oligometastatic nodal recurrence. MATERIALS AND METHODS: Between February 2014 and April 2016, 35 patients across two centres underwent RASND for 68 Ga-PSMA PET/CT-detected oligometastatic nodal recurrence. RASND was performed using targeted pelvic dissection, unilateral extended pelvic template or bilateral extended pelvic template dissection, depending on previous pelvic treatment and extent/location of nodal disease. Complications were reported using the Clavien-Dindo classification system. Definitions of prostate-specific antigen (PSA) treatment response to RASND were defined as 6-week PSA <0.2 ng/mL (broad definition) or PSA <0.05 ng/mL (strict definition) in those who had undergone primary prostatectomy, and 6-week PSA level < post-radiotherapy nadir in those who had undergone primary radiotherapy. Biochemical recurrence (BCR) after RASND was defined as a PSA >0.2 ng/mL or PSA > nadir, for those who had undergone primary prostatectomy and primary radiotherapy, respectively. Predictors of treatment response were analysed using univariate binary logistic regression. RESULTS: A total of 58 lesions suspicious for lymph node metastases (LNM) in 35 patients were detected on 68 Ga-PSMA imaging. A total of 32 patients (91%) had histopathologically proven LNM at RASND, with a total of 87 LNM and a median (interquartile range) of 2 (1-3) LNM per patient. In all, eight patients (23%) experienced complications, all Clavien-Dindo grade ≤2. Treatment response was seen in 15 (43%) and 11 patients (31%), using the broad and strict definitions, respectively. BCR-free survival and clinical recurrence-free survival at a median follow-up of 12 months were 23% and 66%, respectively, for the entire cohort. Bilateral template dissection was the only significant univariate predictor of treatment response in our cohort. CONCLUSIONS: Although RASND appears safe and feasible, less than half of our cohort had a treatment response, and less than a quarter experienced BCR-free survival at 12-month median follow-up. 68 Ga-PSMA imaging underestimates micro-metastatic disease, therefore RASND will rarely be curative. Strict patient selection and restricting RASND to clinical trials is recommended. Long-term follow-up from such trials is required to further assess potential quality of life and mortality benefits.
引用
- Siriwardana A, Thompson J, van Leeuwen PJ, et al. Initial multicentre experience of 68 gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited. BJU Int. 2017. PMID: 28548372. doi:10.1111/bju.13919
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。